查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
高鈣血症治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180655

高鈣血症治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)

Hypercalcemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

全球高鈣血症治療的市場規模，2021年為136億2,890萬美金，預計2022年～2030年的預測期間內以10.7％的年複合成長率擴大，至2030年達到338億5,470萬美元。

全球高鈣血症治療市場，以癌症患者數增加，副甲狀腺機能亢進症相關的高鈣血症盛行率上升，恰當藥物治療療法的可用性等為背景，在預測期間內急速擴大。還有多發性骨髓瘤的發病率上升，外科手術替換的藥物療法的可用性，含美國的已開發國家的有利的償付政策，預期活化全球市場。

本報告提供全球高鈣血症治療市場相關調查分析，市場趨勢，競爭分析，市場動態，各市場區隔、各地區的市場分析，企業簡介等系統性資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 高鈣血症治療市場:競爭分析

  • 主要的高鈣血症治療市場供應商的市場定位
  • 高鈣血症治療市場供應商採用的策略
  • 主要的產業策略
  • 階層分析:2021年對2030年

第4章 高鈣血症治療市場:常量分析和市場動態

  • 簡介
  • 全球高鈣血症治療市場價值(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要機會
  • 促進因素與阻礙因素的影響分析
  • See-Saw分析

第5章 高鈣血症治療市場:各藥物(2020年～2030年)

  • 市場概要
  • 成長、收益分析:2021年對2030年
  • 市場明細
    • Clodronate
    • 擬鈣劑
    • 抑鈣素
    • Denusomab
    • 糖皮質激素
    • 開發平台分析

第6章 北美的高鈣血症治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 北美

第7章 英國、EU的高鈣血症治療市場，2020-2030年，美金(一百萬)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 英國、EU

第8章 亞太地區的高鈣血症治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 亞太地區

第9章 南美的高鈣血症治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 南美

第10章 中東、非洲的高鈣血症治療市場(2020年～2030年)

  • 市場概要
  • 各藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 中東、非洲

第11章 企業簡介

  • Amgen, Inc.
  • Bayer Pharma AG
  • Cipla, Inc.
  • Dr. Reddy's Laboratories, Ltd.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries, Ltd.
Product Code: 138104-08-22

Industry Outlook

The global hypercalcemia treatment market will reach US$ 33,854.7 Mn by 2030 from US$ 13,628.9 Mn in 2021, growing at a CAGR of 10.7% during the forecast period from 2022 to 2030. Hypercalcemia is a condition characterized by the elevated levels of serum calcium ranging above 2.6 mmol/L. The disorder is predominantly associated with two main causes including hypercalcemia of malignancy (HCM) and primary hyperparathyroidism. The disorder occurs in 10% to 20% of the cancer patients, prominently in the breast and lung cancer patients. Furthermore, other factors responsible for hypercalcemia are hereditary factors, severe dehydration, medications, and supplements. The global hypercalcemia treatment market will surge during the forecast period pertaining to the rising number of cancer patients, growing prevalence of hyperparathyroidism-related hypercalcemia, and availability of appropriate drug treatment therapies. Furthermore, rising incidence of multiple myeloma, availability of drug therapy alternatives over surgeries and favorable reimbursement policies in developed countries including the United States expected to fuel global market.

As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market. The key market players are particularly focusing on the chronic kidney disease (CKD) along with the parathyroidism. For instance, US FDA approved a drug manufactured by OPKO Health for the treatment of secondary hyperparathyroidism in adults with CKD. Such approvals will propel the growth of global hypercalcemia market.

"Bisphosphonates expected to retain major market share during the forecast period"

Bisphosphonates is the major segment capturing over 65% of market value share. Bisphosphonates are used to prevent the loss of bone density. Due to the high preference of bisphosphonates, the segment will retain its supremacy in the market during the forecast period. Furthermore, the usage of combination therapy for the treatment of hypercalcemia is increasing, which combines two or more drugs from same or different classes. The high preference of combination therapy in developed country further fuels the growth of bisphosphonates market as these drugs are used predominantly in combination therapy with other drugs and therapies. For instance, many researchers and physicians are evaluating the use of combination of pamidronate and calcitonin. Denusomab market segment will be the fastest growing market segment during the forecast period followed by calcitonin. The aforementioned treatment pattern adopted by physicians is expected to catalyze the growth of hypercalcemia drugs market.

"Asia Pacific to Experience Lucrative Growth with Double Digit CAGR during the Forecast Period"

The Asia Pacific expected to witness lucrative growth during the forecast period owing to high awareness and rising adoption of the hypercalcemia treatment drugs. Furthermore, increasing prevalence of hyperparathyroidism-related hypercalcemia and growing incidence of multiple myeloma in the region expected to fuel the market. Additionally, the rising accessibility of drug therapies and favorable reimbursement policies in the developing countries further contributes to the double-digit growth of the Asia Pacific market.

In 2021, North America dominated the hypercalcemia treatment market with over 34% of the market share, in terms of market value. The United States expected to dominate the North America market due to high awareness regarding hypercalcemia and associated disorders. Furthermore, growing prevalence of malignancy-related hypercalcemia among cancer patients will further catalyze the growth of the North America hypercalcemia market.

"Approval of Promising Pipeline Candidates Expected to Fuel the Market Growth"

The global hypercalcemia treatment market is highly fragmented due to the presence of numerous players. However, some of the players dominated the market attributing to the development of effective drugs, novel product launches, and strategic market initiatives. Furthermore, the unmet needs of the disease compel manufacturers to focus on R&D and develop products that are more efficient. For instance, Kyowa Hakko Kirin Co., Ltd. has completed phase III clinical trials for KHK7580 and filled a NDA (New Drug Application) in Japan. Furthermore, the manufacturers is developing another candidate, KRN1493, for secondary hyperparathyroidism. Expected approval of such promising candidates will fuel the market during the forecast period. Additionally, key players in hypercalcemia market include Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin, OPKO Health, Merck & Co., Abbive, Inc., and Pfizer, Inc.

This research study further elucidates the key qualitative market assessment parameters including key market trends, DROs, to assist in holistic understanding of global hypercalcemia treatment market. Additionally, the major players are mapped graphically based on their business strength, market strategies and product offering. The research study further provides attractive investment proposition based on the extensive geographical research. Major manufacturers profiled in the report include AbbVie, Inc., Merck & Co., OPKO Health, Novartis AG, Amgen, Inc., Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin and Pfizer, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hypercalcemia Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Hypercalcemia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

Clodronate

Etidronate

Ibandronate

Pamidronate

Zoledronic acid

Calcimimetic Agents

Calcitonin

Denusomab

Glucocorticoids

Pipeline Analysis

Phase III

KHK7580

Phase II & I (Tabular Information)

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Hypercalcemia Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Hypercalcemia Treatment market?

Which is the largest regional market for Hypercalcemia Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Hypercalcemia Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Hypercalcemia Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Hypercalcemia Treatment Market
  • 2.2. Global Hypercalcemia Treatment Market, By Drug, 2021 (US$ Million)
  • 2.3. Global Hypercalcemia Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Hypercalcemia Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Hypercalcemia Treatment Market Vendors
  • 3.2. Strategies Adopted by Hypercalcemia Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Hypercalcemia Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Hypercalcemia Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Clodronate
      • 5.3.1.1. Etidronate
      • 5.3.1.2. Ibandronate
      • 5.3.1.3. Pamidronate
      • 5.3.1.4. Zoledronic acid
    • 5.3.2. Calcimimetic Agents
    • 5.3.3. Calcitonin
    • 5.3.4. Denusomab
    • 5.3.5. Glucocorticoids
    • 5.3.6. Pipeline Analysis
      • 5.3.6.1. Phase III
      • 5.3.6.2. KHK7580
      • 5.3.6.3. Phase II & I (Tabular Information)

6. North America Hypercalcemia Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
  • 6.3.Hypercalcemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)

7. UK and European Union Hypercalcemia Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
  • 7.3.Hypercalcemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)

8. Asia Pacific Hypercalcemia Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
  • 8.3.Hypercalcemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)

9. Latin America Hypercalcemia Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
  • 9.3.Hypercalcemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)

10. Middle East and Africa Hypercalcemia Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
  • 10.3.Hypercalcemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Hypercalcemia Treatment Market: By Drug, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Amgen, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bayer Pharma AG
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Cipla, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Dr. Reddy's Laboratories, Ltd.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Mylan N.V.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Novartis AG
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Pfizer, Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Sun Pharmaceutical Industries, Ltd.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 2 Global Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 3 Global Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 4 North America Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 North America Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 6 North America Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 7 U.S. Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 8 U.S. Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 9 U.S. Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 10 Canada Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 11 Canada Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 12 Canada Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 19 UK Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 20 UK Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 21 UK Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 22 Germany Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 23 Germany Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 24 Germany Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 25 Spain Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 26 Spain Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 27 Spain Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 28 Italy Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 29 Italy Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 30 Italy Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 31 France Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 32 France Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 33 France Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 37 Asia Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 38 Asia Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 39 Asia Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 40 China Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 41 China Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 42 China Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 43 Japan Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 44 Japan Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 45 Japan Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 46 India Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 47 India Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 48 India Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 49 Australia Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 50 Australia Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 51 Australia Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 52 South Korea Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 53 South Korea Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 54 South Korea Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 55 Latin America Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 56 Latin America Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 57 Latin America Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 58 Brazil Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 59 Brazil Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 60 Brazil Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 61 Mexico Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 62 Mexico Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 63 Mexico Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 70 GCC Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 71 GCC Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 72 GCC Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 73 Africa Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 74 Africa Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 75 Africa Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Hypercalcemia Treatment Market By Drug, 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Hypercalcemia Treatment Market By Clodronate, 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Hypercalcemia Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Hypercalcemia Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Hypercalcemia Treatment Market: Quality Assurance
  • FIG. 5 Global Hypercalcemia Treatment Market, By Drug, 2021
  • FIG. 6 Global Hypercalcemia Treatment Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Hypercalcemia Treatment Market, 2021
  • FIG. 8 Market Positioning of Key Hypercalcemia Treatment Market Players, 2021
  • FIG. 9 Global Hypercalcemia Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Hypercalcemia Treatment Market, By Drug, 2021 Vs 2030, %
  • FIG. 11 U.S. Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 France Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 China Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 India Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Hypercalcemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Hypercalcemia Treatment Market (US$ Million), 2020 - 2030